TScan Therapeutics CEO steps down, shares fall
31/03/2023 16:41
** Shares of drug developer TScan Therapeutics Inc TCRX.O
fall 17% to $2.13
** David Southwell has stepped down as CEO and member of the
board, effective March 27, company says
** The board has appointed Gavin MacBeath as acting CEO,
effective March 28
** Despite session's loss, stock up ~39% YTD
(Reporting by Sriparna Roy)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing